Lakewood-Amedex Biotherapeutics redeems all remaining preferred shares for $1.27 million
LABT•Lakewood-Amedex Biotherapeutics redeemed all 127,097 remaining Series C Convertible Preferred Stock shares for $1.27 million, using cash on hand. The company said no preferred stock or indebtedness for borrowed money remains outstanding.
1. Redemption completed
Lakewood-Amedex Biotherapeutics completed the redemption under a November 2, 2026, agreement with Shakawe Capital. The company said the redemption eliminates potential dilution from Series C Preferred Stock conversions and removes associated financing restrictions.
